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Outline: 
1. Background:  
•  What is CHARGE Syndrome? 
•  What is CHD7 gene? 
2. Rationale: What are the reasons for doing this research? 
3. Goal: What is the main objective? 
4. Key Method: What is CRIPSR/CAS9? 
5. Results: Data presentation 
6. Summary 
7. Acknowledgements 
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What is CHARGE Syndrome? 
•  CHARGE syndrome is a cluster of life-threatening genetic disorders that 
affects multiple organs; typically, children born with CHARGE 
syndrome show several phenotypes: 
 
Coloboma (a hole in the eye),  
Heart defect,  
Atresia choanae (back of nasal passage is blocked), 
Retarded growth and development,  
Genital hypoplasia,  
Ear anomalies/deafness 
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Sequence-Based Delineation of a Balanced De Novo 
Translocation 
Deep Sequencing and Analysis Timeline 
An example of CHARGE syndrome diagnosis in vivo coupled with 
DNA sequencing 
Nature Genetics  36, 955 - 957 (2004)  
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CHARGE syndrome is a neglected disease. Thus, we understand very  
little about the function of CHD7 protein. 
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Nature Genetics  36, 955 - 957 (2004)  
Mutations in a chromodomain gene family cause  
CHARGE syndrome 
Dominant loss-of-function mutations 
in the gene encoding 
chromodomain helicase DNA 
binding protein 7 (CHD7), an 
ATP-dependent chromatin 
remodeler, is the main cause of 
CHARGE syndrome. 
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Trends Genet. 2015 Oct; 31(10): 600–611.  
Proposed Model of CHD7 Action at Enhancers 
1.  Remodel chromatin 
2.  May bind to DNA directly 
3.  May repress the action of transcription factors 
including p53 
4.  Mutation of CHD7 might affect lifespan stem 
cells 
Proposed functions of CHD7 
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To address this deficiency in our knowledge, we proposed to use 
CRISPR/Cas9 to model CHARGE disease-in-a-dish. 
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How does CRISPR/Cas9 work? 
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Emmanuelle Charpentier (left),  
Jennifer Doudna (right) 
Designing CHD7 gRNA for CRISPR/Cas9  
Select 23-250 nucleotide and search for gRNA using the MIT Zhang lab software 
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An example of designing sgRNAs using the UCSC genome browser 


















CHD7 Target 1- gRNA:  396  GAGGCATGGGCAATCCTTTG 
CHD7 Target 2- gRNA:  1234  GCACTTCCCGGCCTGACTTG 
CHD7 Target 3- gRNA   1322  GTGCCATGGGAATCGGACAG 
CHD7  exon-1 
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GAGGCATGGGCAATCCTTTG Pam sequence 
Making sure that our gRNA matches the target sequence  
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However, if we introduce 3 nucleotide mismatches, there could 
be 5 off-target effects 
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CHD7 Target 1- gRNA:  396  GAGGCATGGGCAATCCTTTG 
CHD7 Target 2- gRNA:  1234  GCACTTCCCGGCCTGACTTG 
CHD7 Target 3- gRNA   1322  GTGCCATGGGAATCGGACAG 
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Transform E Coli and grow in an ampicillin containing LB plates
Pick transformed E. coli colony from plates
Grow E coli in 100ml LB medium culture overnight
Prepare DNAs, quan/fy and check it in a agarose gel
Neil Wary 
1    2    3     4    5    6 
Preparation of DNAs (sgRNAs) in pLentivirus vector 
LB plate 
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Generating lentivirus all-in-one CHD7 sgRNA  
Transfect 
with sgRNA-pLentivirus  
Overnight 
Split into 3 dishes 
Add puromycin to kill  
untransfected cells 
Expand, freeze puromycin resistant 
cells; and collect virus supernatant. 
Amphopack cell lines  
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Normal human fibroblast cells infected with 




are used to  
infect fibroblast cells 
+ CRISPR/Cas9 –CHD7-gRNA 
48 hours 
Add puromycin 
Day-1 Day-3 Day-28 
Puromycin resistant 
cells are now CRISPR-ED. 
Make DNAs for PCR 
and DNA sequencing  
Freeze cells in liquid N2 
Expand cells and do functional studies 
Experiment#1: 
Experiments#2-7: 
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Diagnostic test for CHD7 gene editing 
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An example of CHD7 gene editing DNA sequencing result 
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Validation of CHD7 gene editing by Western blot  
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An example of CHD7 mutant fibroblast cells 
Control 
A B 
50 µm 50 µm 
40X 40X 
CHD7(mt) 
Green: Tubulin;  Red: actin:  Blue: DAPI (nucleus) 
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Summary: 
Here, we: 
1.  Generated CRISPR/Cas9 lentivirus using three different sgRNAs. 
2.  Produced human fibroblast cells, in which CHD7 gene is mutated 
or deleted. 
3.  Used DNA sequencing method to identify and characterize the 
exact mutation. 
4.  Gearing up to carry-out functional study of this mutant gene 
using genome edited fibroblast cells. 
Future Study: 
These novel cell lines should become useful to screen drugs that 
could either increase (agonist) or decrease (antagonist) the expression 
of CHD7 – in the long run may aid in improving the lives of 
CHARGE children. 
 23 of 25 Outline      Background      Question      Methods      Data/Results      Summary/Future      Acknowledgements IMSAloquium 2017  
References 
1.  Zentner GE, Layman WS, Martin DM, Scacheri PC. Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome. Am J Med Genet A. 2010;152A(3):674-86.  
2.  Bergman JE, Janssen N, Hoefsloot LH, Jongmans MC, Hofstra RM, van Ravenswaaij-Arts CM. CHD7 mutations and CHARGE syndrome: the clinical implications of an 
expanding phenotype. J Med Genet. 2011;48(5):334-42.  
3.  Janssen N, Bergman JE, Swertz MA, Tranebjaerg L, Lodahl M, Schoots J, Hofstra RM, van Ravenswaaij-Arts CM, Hoefsloot LH. Mutation update on the CHD7 gene involved in 
CHARGE syndrome. Hum Mutat. 2012;33(8):1149-60.  
4.  Palumbo O, Palumbo P, Stallone R, Palladino T, Zelante L, Carella M. 8q12.1q12.3 de novo microdeletion involving the CHD7 gene in a patient without the major features of 
CHARGE syndrome: case report and critical review of the literature. Gene. 2013;513(1):209-13.  
5.  Martin DM. Epigenetic Developmental Disorders: CHARGE syndrome, a case study. Curr Genet Med Rep. 2015;3(1):1-7. 
6.  Wong MT, Schölvinck EH, Lambeck AJ, van Ravenswaaij-Arts CM. CHARGE syndrome: a review of the immunological aspects. Eur J Hum Genet. 2015;23(11):1451-9. 
7.  Busa T, Legendre M, Bauge M, Quarello E, Bretelle F, Bilan F, Sigaudy S, Gilbert-Dussardier B, Philip N. Prenatal findings in children with early postnatal diagnosis of CHARGE 
syndrome. Prenat Diagn. 2016;36(6):561-7.  
8.  Wells C, Loundon N, Garabedian N, Wiener-Vacher S, Cordier-Bouvier MD, Goudeffroye G, Attié-Bitach T, Marlin S. A case of mild CHARGE syndrome associated with a 
splice site mutation in CHD7. Eur J Med Genet. 2016;59(4):195-7. 
9.  Whittaker DE, Riegman KL, Kasah S, Mohan C, Yu T, Sala BP, Hebaishi H, Caruso A, Marques AC, Michetti C, Smachetti ME, Shah A, Sabbioni M, Kulhanci O, Tee WW, 
Reinberg D, Scattoni ML, Volk H, McGonnell I, Wardle FC, Fernandes C, Basson MA. The chromatin remodeling factor CHD7 controls cerebellar development by regulating 
reelin expression. J Clin Invest. 2017;127(3):874-887.  
10.  Ohta S, Yaguchi T, Okuno H, Chneiweiss H, Kawakami Y, Okano H. CHD7 promotes proliferation of neural stem cells mediated by MIF. Mol Brain. 2016;9(1):96.  
11.  Jones KM, Sarić N, Russell JP, Andoniadou CL, Scambler PJ, Basson MA. CHD7 maintains neural stem cell quiescence and prevents premature stem cell depletion in the adult 
hippocampus. Stem Cells. 2015;33(1):196-210.  
12.  Feng W, Liu HK. Epigenetic regulation of neuronal fate determination: the role of CHD7. Cell Cycle. 2013;12(24):3707-8.  
13.  Kim KH, Roberts CW. CHD7 in charge of neurogenesis. Cell Stem Cell. 2013;13(1):1-2. 
14.  1: Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 
2012;337(6096):816-21.  
15.  Charpentier E, Doudna JA. Biotechnology: Rewriting a genome. Nature. 2013;495(7439):50-1.  
16.  Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.  
17.  Bosley KS, Botchan M, Bredenoord AL, Carroll D, Charo RA, Charpentier E, Cohen R, Corn J, Doudna J, Feng G, Greely HT, Isasi R, Ji W, Kim JS, Knoppers B, Lanphier E, Li 
J, Lovell-Badge R, Martin GS, Moreno J, Naldini L, Pera M, Perry AC, Venter JC, Zhang F, Zhou Q. CRISPR germline engineering--the community speaks. Nat Biotechnol. 
2015;33(5):478-86. 
 
224 of 25 Outline      Background      Question      Methods      Data/Results      Summary/Future      Acknowledgements IMSAloquium 2017  
Acknowledgements 
Neil Wary 
Illinois Mathematics and Science Academy 
nwary@imsa.edu 
 
Jugajyoti Baruah, MS 
Suhnrita Chaudhuri, PhD 
Ryan Hitzman 
Victoria Mastej 
Kishore K. Wary, PhD 
25 of 25 Outline      Background      Question      Methods      Data/Results      Summary/Future      Acknowledgements IMSAloquium 2017  
The SIR Department 
